AXN 027
Alternative Names: AXN-027Latest Information Update: 10 Jan 2025
At a glance
- Originator AXONIS Therapeutics
- Class Analgesics; Antiepileptic drugs; Small molecules
- Mechanism of Action K Cl-cotransporter agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Epilepsy; Neuropathic pain; Spinal cord injuries
Most Recent Events
- 10 Jan 2025 Phase-I clinical trials in Epilepsy (PO), before January 2025 (AXONIS Therapeutics pipeline, January 2025)
- 10 Jan 2025 Phase-I clinical trials in Neuropathic pain (PO), before January 2025 (AXONIS Therapeutics pipeline, January 2025)
- 10 Jan 2025 Phase-I clinical trials in Spinal cord injuries (PO), before January 2025 (AXONIS Therapeutics pipeline, January 2025)